- Home
- CHRS vs BTMD Comparison
CHRS vs BTMD Comparison
Compare CHRS & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- BTMD
- Stock Information
- Founded
- CHRS 2010
- BTMD 2012
- Country
- CHRS United States
- BTMD United States
- Employees
- CHRS N/A
- BTMD N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- BTMD Medicinal Chemicals and Botanical Products
- Sector
- CHRS Health Care
- BTMD Health Care
- Exchange
- CHRS Nasdaq
- BTMD Nasdaq
- Market Cap
- CHRS 112.5M
- BTMD 102.3M
- IPO Year
- CHRS 2014
- BTMD N/A
- Fundamental
- Price
- CHRS $0.76
- BTMD $4.10
- Analyst Decision
- CHRS Strong Buy
- BTMD Strong Buy
- Analyst Count
- CHRS 4
- BTMD 1
- Target Price
- CHRS $5.26
- BTMD $8.00
- AVG Volume (30 Days)
- CHRS 1.7M
- BTMD 182.3K
- Earning Date
- CHRS 05-12-2025
- BTMD 05-07-2025
- Dividend Yield
- CHRS N/A
- BTMD N/A
- EPS Growth
- CHRS N/A
- BTMD 201.68
- EPS
- CHRS N/A
- BTMD 0.60
- Revenue
- CHRS $272,251,000.00
- BTMD $199,379,000.00
- Revenue This Year
- CHRS N/A
- BTMD $5.93
- Revenue Next Year
- CHRS N/A
- BTMD $9.07
- P/E Ratio
- CHRS N/A
- BTMD $6.87
- Revenue Growth
- CHRS 19.87
- BTMD 6.44
- 52 Week Low
- CHRS $0.66
- BTMD $3.04
- 52 Week High
- CHRS $2.43
- BTMD $8.44
- Technical
- Relative Strength Index (RSI)
- CHRS 36.67
- BTMD 63.35
- Support Level
- CHRS $0.71
- BTMD $3.85
- Resistance Level
- CHRS $1.06
- BTMD $4.40
- Average True Range (ATR)
- CHRS 0.08
- BTMD 0.25
- MACD
- CHRS -0.03
- BTMD 0.09
- Stochastic Oscillator
- CHRS 12.44
- BTMD 76.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.